Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors by virtual screening

被引:11
|
作者
Zhou, Yeheng [1 ,2 ]
Peng, Jiale [1 ]
Li, Penghua [1 ]
Du, Haibo [1 ]
Li, Yaping [1 ]
Li, Yingying [1 ]
Zhang, Li [1 ]
Sun, Wei [2 ]
Liu, Xingyong [1 ]
Zuo, Zhili [1 ,2 ]
机构
[1] Sichuan Univ Sci & Engn, Sch Chem Engn, Zigong, Peoples R China
[2] Chinese Acad Sci, State Key Lab Phytochem & Plant Resources West Ch, Kunming Inst Bot, Kunming, Yunnan, Peoples R China
关键词
IDO1; Molecular docking; HipHop pharmacophore; 3D-QSAR; PAINS; PHENYL BENZENESULFONYLHYDRAZIDES; THERAPEUTIC TARGET; CRYSTAL-STRUCTURES; DERIVATIVES; DOCKING; MECHANISM;
D O I
10.1016/j.compbiolchem.2018.11.024
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In this study, a combination of virtual screening methods were utilized to identify novel potential indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. A series of IDOL potential inhibitors were identified by a combination of following steps: Lipinski's Rule of Five, Veber rules filter, molecular docking, HipHop pharmacophores, 3D-Quantitative structure activity relationship (3D-QSAR) studies and Pan-assay Interference Compounds (PAINS) filter. Three known categories of IDO1 inhibitors were used to constructed pharmacophores and 3D-QSAR models. Four point pharmacophores (RI-IDA) of IDOL inhibitors were generated from the training set. The 3D-QSAR models were obtained using partial least squares (PLS) analyze based on the docking conformation alignment from the training set. The leave-one-out correlation (q(2)) and non-cross-validated correlation coefficient (r(pred)(2)) of the best CoMFA model were 0.601 and 0.546, and the ones from the best CoMSIA model were 0.506 and 0.541, respectively. Six hits from Specs database were identified and analyzed to confirm their binding modes and key interactions to the amino acid residues in the protein. This work may provide novel backbones for new generation of inhibitors of IDOL.
引用
收藏
页码:306 / 316
页数:11
相关论文
共 50 条
  • [31] Discovery of a Novel Scaffold as an Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Based on the Pyrrolopiperazinone Alkaloid, Longamide B
    Shiokawa, Zenyu
    Kashiwabara, Emi
    Yoshidome, Daisuke
    Fukase, Koichi
    Inuki, Shinsuke
    Fujimoto, Yukari
    CHEMMEDCHEM, 2016, 11 (24) : 2682 - 2689
  • [32] Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
    Roehrig, Ute F.
    Majjigapu, Somi Reddy
    Vogel, Pierre
    Reynaud, Aline
    Pojer, Florence
    Dilek, Nahzli
    Reichenbach, Patrick
    Ascencao, Kelly
    Irving, Melita
    Coukos, George
    Michielin, Olivier
    Zoete, Vincent
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2022, 37 (01) : 1773 - 1811
  • [33] Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy
    Tang, Kai
    Wang, Bo
    Yu, Bin
    Liu, Hong-Min
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 227
  • [34] Indoleamine 2,3-Dioxygenase 1 (IDO1) in Kidney Transplantation: A Guardian against Rejection
    Wisnicki, Krzysztof
    Donizy, Piotr
    Halon, Agnieszka
    Wawrzonkowski, Patryk
    Janczak, Dariusz
    Krajewska, Magdalena
    Banasik, Miroslaw
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (24)
  • [35] Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with inflammation in systemic sclerosis
    Rutella, Sergio
    De Santis, Maria
    Bonanno, Giuseppina
    Procoli, Annabella
    Mariotti, Andrea
    Corallo, Maria
    Novarese, Linda
    Bosello, Silvia
    Scambia, Giovanni
    De Cristofaro, Raimondo
    Ferraccioli, Gianfranco
    JOURNAL OF IMMUNOLOGY, 2011, 186
  • [36] Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice
    Aslamkhan, Amy G.
    Xu, Qiuwei
    Loughlin, Amy
    Vu, Heather
    Pacchione, Stephen
    Bhatt, Bhavana
    Garfinkel, Ivy
    Styring, Tara Grady
    LaFranco-Scheuch, Lisa
    Pearson, Kara
    Reynolds, Spencer
    Li, Nianyu
    Zhou, Heather
    Miller, J. Richard
    Solban, Nicolas
    Bass, Alan
    Glaab, Warren E.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 406
  • [37] Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
    Komiya, Takefumi
    Huang, Chao H.
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [38] Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme
    Hamilton, Matthew M.
    Mseeh, Faika
    McAfoos, Timothy J.
    Leonard, Paul G.
    Reyna, Naphtali J.
    Harris, Angela L.
    Xu, Alan
    Han, Michelle
    Soth, Michael J.
    Czako, Barbara
    Theroff, Jay P.
    Mandal, Pijus K.
    Burke, Jason P.
    Virgin-Downey, Brett
    Petrocchi, Alessia
    Pfaffinger, Dana
    Rogers, Norma E.
    Parker, Connor A.
    Yu, Simon S.
    Jiang, Yongying
    Krapp, Stephan
    Lammens, Alfred
    Trevitt, Graham
    Tremblay, Martin R.
    Mikule, Keith
    Wilcoxen, Keith
    Cross, Jason B.
    Jones, Philip
    Marszalek, Joseph R.
    Lewis, Richard T.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (15) : 11302 - 11329
  • [39] Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions
    Tomek, Petr
    Palmer, Brian D.
    Flanagan, Jack U.
    Sun, Chuanwen
    Raven, Emma L.
    Ching, Lai-Ming
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 126 : 983 - 996
  • [40] Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO)
    Zhang, Shengnan
    Guo, Leilei
    Yang, Dan
    Xing, Zikang
    Li, Weirui
    Kuang, Chunxiang
    Yang, Qing
    BIOORGANIC CHEMISTRY, 2020, 104